Study details
Enrolling now
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Divaya Bhutani
NCT IDNCT05346809ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
39
Study length
about 3.5 years
Ages
18+
Locations
2 sites in MI, NY
What this study is about
This trial is testing if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma after stem cell transplant. Participants will receive either standard procedures or Isatuximab along with those procedures, randomly assigned by a computer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Standard Procedures
- 2.Take Isatuximab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
isatuximab
Endpoints
Secondary: Number of Adverse Events
Body systems
Oncology